Spencer Feldman

Prostate-specific antigen responses were similar between transdermal estradiol and hormone therapy combined with androgen receptor inhibitors in prostate cancer.

Patients with appendiceal adenocarcinoma face increased risk of secondary cancers, including colorectal, within 10 years, per 2025 ASCO GI findings.

A study found that reducing the dose of pembrolizumab in patients with advanced stage non–small cell lung cancer did not significantly affect overall survival compared to the standard dose.